Tarsus (TARS) Q1 2026 Earnings Transcript

Tarsus Pharmaceuticals reported Q1 XTENVI net product sales of $145.4 million, up more than 85% year over year, and reiterated full-year 2026 guidance for $670 million to $700 million in net product sales with ~93% gross margin. Management also highlighted improving prescription depth, nearly 50% weekly prescribing among target eye care physicians, and retreatment rates in the mid-to-high teens moving toward a 20% steady-state target. The company advanced two Phase II programs, TPO5 for Lyme disease and TPO4 for ocular rosacea, while securing a $15 million regulatory milestone from Grand Pharma for TPO3 approval in Greater China.

Analysis

The core trade is that TARS is transitioning from a launch story to a behavior-change story: once physicians move from opportunistic treatment to systematic screening, the TAM expands without needing proportionate DTC spend. That creates a second-order margin lever because every incremental prescriber and retreatment cohort should compound rather than reset, which makes the 2026 guide look increasingly conservative if the KAL rollout hits in Q3 as planned. The key nuance is that the company is now selling a habit, not just a product, and habits tend to show up in utilization persistence before they show up in formal sell-side model revisions.

The market is likely underestimating how much of the upside is already embedded in the current growth rate versus how much can still come from mix and frequency. If retreatment moves from the mid/high-teens toward the stated steady-state 20%, that is not just a volumetric tailwind; it signals clinical protocol adoption, which historically reduces churn and improves forecast visibility. The DTC data also matters less as a direct conversion metric and more as a proof-point that patient pull is starting to reduce the salesforce burden per new Rx, improving capital efficiency into 2H26.

The bigger contrarian risk is not competition this year; it is execution dilution. With three pipeline shots, international complexity, and a planned sales expansion, management could overpromise on category expansion while the base business remains highly seasonal and insurance-sensitive. A negative surprise in gross-to-net or a slower-than-expected Q3 KAL ramp would likely compress the multiple fast because the stock is now priced for continued outperformance, not just good growth.

On the pipeline, TPO5 and TPO4 are strategically interesting but economically optional in the next 12 months; they are catalysts for narrative duration, not near-term earnings. That means the stock can rerate on commercial durability alone, while pipeline data mainly serves as downside protection for the multiple rather than a P&L driver. For traders, the cleaner expression is to own near-term commercial upside and treat pipeline value as free optionality, not as the primary reason to own the shares.

Key Decisions for Investors

• Long TARS into the next 1-2 quarters on continued Rx momentum and KAL deployment; expect a positive re-rating if Q2/Q3 prescription growth confirms that screening behavior is broadening beyond the initial cataract/dry eye cohort.
• Buy TARS June/September calls or a call spread to express upside convexity ahead of the Q3 KAL rollout; thesis is that the market underprices incremental depth-of-prescribing, with limited downside if the business is already executing near guidance.
• Use any post-earnings pullback tied to gross-to-net or seasonality noise to add to TARS; risk/reward improves if the stock sells off on transitory cadence issues while the full-year guide remains intact.
• Avoid shorting GKOS outright as a hedge; if anything, pair long TARS vs short a basket of slower-growth ophthalmology names only if you want to isolate launch-durability alpha, because the competitive read-through here is more about category expansion than displacement.
• Trim or hedge TARS only if 2H26 KAL contribution is clearly lagging and gross-to-net stays sticky; that would be the first sign that the business is plateauing before the pipeline can matter.